Summary sheet
European R&D site(s) of the promoter.
The project comprises the promoter’s ongoing R&D programme 2007-2009 and includes expenditures incurred in the promoter’s European facilities for internal personnel and other operating costs as well as expenses for clinical trials, cooperation, licences, patent registration and laboratory equipment.
RDI activities will not materially change current RDI practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11.
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement.
This RDI project, encompassing leading R&D in biopharmaceutical and in medical devices aims at the development of innovative therapies and products targeting life-threatening diseases.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications